Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
10:31am, Monday, 09'th Jun 2025
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript
07:09am, Thursday, 05'th Jun 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies Global Healthcare Conference June 4, 2025 9:20 AM ET Company Participants Christine Fox - Executive VP of U.S. Commercial Business Eric A.
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
05:30pm, Tuesday, 03'rd Jun 2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously an
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously an
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results fro
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
09:00pm, Friday, 30'th May 2025
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the present
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
08:00am, Thursday, 29'th May 2025
TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acce
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
12:11pm, Wednesday, 28'th May 2025
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
03:06am, Wednesday, 28'th May 2025
The amount of data investors digest daily on Wall Street can sometimes feel overwhelming. Over the last six weeks, investors have navigated their way through earnings season, a Federal Reserve Open Ma
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
05:30pm, Tuesday, 27'th May 2025
Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celi
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
04:30pm, Tuesday, 27'th May 2025
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming
Teva initiated with bullish view at Truist, here's why
04:14pm, Tuesday, 27'th May 2025
05 Jun
Why Is Teva Stock Trading Higher On Tuesday?
03:44pm, Tuesday, 27'th May 2025
Teva Pharmaceutical Industries Ltd TEVA and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
12:21pm, Tuesday, 27'th May 2025
TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.
REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnolo
